215 related articles for article (PubMed ID: 22213096)
21. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells.
Flowers LO; Subramaniam PS; Johnson HM
Oncogene; 2005 Mar; 24(12):2114-20. PubMed ID: 15688010
[TBL] [Abstract][Full Text] [Related]
22. Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells.
Huang WL; Yeh HH; Lin CC; Lai WW; Chang JY; Chang WT; Su WC
Mol Cancer; 2010 Dec; 9():309. PubMed ID: 21122157
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.
Wang X; Yang L; Huang F; Zhang Q; Liu S; Ma L; You Z
Immunol Lett; 2017 Apr; 184():7-14. PubMed ID: 28223102
[TBL] [Abstract][Full Text] [Related]
24. Posttranscriptional regulation of T-type Ca(2+) channel expression by interleukin-6 in prostate cancer cells.
Weaver EM; Zamora FJ; Hearne JL; Martin-Caraballo M
Cytokine; 2015 Dec; 76(2):309-320. PubMed ID: 26205261
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth.
Culig Z; Bartsch G; Hobisch A
Mol Cell Endocrinol; 2002 Nov; 197(1-2):231-8. PubMed ID: 12431817
[TBL] [Abstract][Full Text] [Related]
26. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
[TBL] [Abstract][Full Text] [Related]
27. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
Sanford DC; DeWille JW
Prostate; 2005 May; 63(2):143-54. PubMed ID: 15486993
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 Induces Myogenic Differentiation via JAK2-STAT3 Signaling in Mouse C2C12 Myoblast Cell Line and Primary Human Myoblasts.
Steyn PJ; Dzobo K; Smith RI; Myburgh KH
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31652937
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.
Puhr M; Santer FR; Neuwirt H; Susani M; Nemeth JA; Hobisch A; Kenner L; Culig Z
Cancer Res; 2009 Sep; 69(18):7375-84. PubMed ID: 19738059
[TBL] [Abstract][Full Text] [Related]
30. Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice.
Shanmugam MK; Rajendran P; Li F; Nema T; Vali S; Abbasi T; Kapoor S; Sharma A; Kumar AP; Ho PC; Hui KM; Sethi G
J Mol Med (Berl); 2011 Jul; 89(7):713-27. PubMed ID: 21465181
[TBL] [Abstract][Full Text] [Related]
31. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
32. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
[TBL] [Abstract][Full Text] [Related]
33. Activation of TGF-β - SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK.
Natani S; Sruthi KK; Asha SM; Khilar P; Lakshmi PSV; Ummanni R
Cell Signal; 2022 Mar; 91():110240. PubMed ID: 34986386
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
35. Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells.
Tassidis H; Culig Z; Wingren AG; Härkönen P
Prostate; 2010 Oct; 70(14):1491-500. PubMed ID: 20687222
[TBL] [Abstract][Full Text] [Related]
36. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP.
Spiotto MT; Chung TD
Prostate; 2000 Feb; 42(2):88-98. PubMed ID: 10617865
[TBL] [Abstract][Full Text] [Related]
37. Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.
Kanayama M; Hayano T; Koebis M; Maeda T; Tabe Y; Horie S; Aiba A
Prostate; 2017 Nov; 77(15):1489-1498. PubMed ID: 28905415
[TBL] [Abstract][Full Text] [Related]
38. Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity.
Jorvig JE; Chakraborty A
Anticancer Drugs; 2015 Feb; 26(2):160-6. PubMed ID: 25243457
[TBL] [Abstract][Full Text] [Related]
39. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
40. [Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].
Ou YH; Jiang YD; Li Q; Zhuang YJ; Dang Q; Tan WL
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jun; 38(6):723-730. PubMed ID: 29997096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
